<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803216</url>
  </required_header>
  <id_info>
    <org_study_id>Digestion-02</org_study_id>
    <nct_id>NCT02803216</nct_id>
  </id_info>
  <brief_title>Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori</brief_title>
  <official_title>Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori: a Prospective, Double-blinded, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiyuan Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Traditional Chinese Medicine (TCM) decoction and
      powder combined with standard triple therapy on improving eradication rate of Helicobacter
      Pylori (H. pylori).A multi-center randomized control clinical trial design was adopted in the
      trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate</measure>
    <time_frame>13C or 14C urea breath test was performed at four weeks after western medicine termination.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</measure>
    <time_frame>at baseline, and every week up to four weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">576</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>standard triple region</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this group were given 10-day standard triple therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard triple region +2-week TCM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group were given 10 days of standard triple therapy + 2-week Xiang-sha-liu-jun decoction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard triple region +4-week TCM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group were given 10days of standard triple therapy + 4-week Xiang-sha-liu-jun decoction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard triple region</intervention_name>
    <description>ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).</description>
    <arm_group_label>standard triple region</arm_group_label>
    <arm_group_label>standard triple region +2-week TCM</arm_group_label>
    <arm_group_label>standard triple region +4-week TCM</arm_group_label>
    <other_name>omeprazole, amoxicillin, clarithromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-week Xiang-sha-liu-jun decoction</intervention_name>
    <description>2-week Xiang-sha-liu-jun decoction, bid.</description>
    <arm_group_label>standard triple region +2-week TCM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4-week Xiang-sha-liu-jun decoction</intervention_name>
    <description>4-week Xiang-sha-liu-jun decoction, bid.</description>
    <arm_group_label>standard triple region +4-week TCM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  those who met chronic gastritis (chronic superficial gastritis and chronic atrophic
             gastritis) diagnostic criteria;

          -  aged between 18-65 years old;

          -  positive H. pylori infection confirmed by two or more methods of different

          -  principles (stop using PPI, H2RA, bismuth, and antibiotics since two weeks before
             examination);

          -  patients were informed consent and willing to accept corresponding treatments.

        Exclusion criteria:

          -  Patients having chronic atrophic gastritis with severe dysplasia, upper
             gastrointestinal bleeding, peptic ulcers, and gastrointestinal tumors;

          -  digestive organic disease (such as chronic pancreatitis, cirrhosis, etc.), or systemic
             diseases affecting intestinal motility (such as hyperthyroidism, diabetes mellitus,
             chronic renal insufficiency, mental, and neurological diseases, etc.);

          -  those who were accompanied by serious heart, liver and other major organs lesions,
             blood diseases, and cancer (ALT, AST two times higher than normal value);

          -  those who had taken medicines that might affect H. pylori detection results within two
             weeks (antacids, H2RA, PPIs, bismuth and antibiotics, etc.);

          -  pregnant and lactating women; patients with history of systematic and neuropsychiatric
             disorders; those who had history of any drug allergy; and those who were participating
             in other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xudong Tang, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>XiYuan Hospital of China Academy of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

